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Abstract
Background
Increasing access to clinically beneficial targeted cancer medicines is a challenge in every
country due to their high cost. We describe the interplay of innovative policies and programs
involving multiple stakeholders to facilitate access to these medicines in Thailand, as well
as the utilization of selected targeted therapies over time.
Methods
We selected two medicines on the 2013 Thai national list of essential medicines (NLEM)
[letrozole and imatinib] and three unlisted medicines for the same indications [trastuzumab,
nilotinib and dasatinib]. We created timelines of access policies and programs for these
products based on scientific and grey literature. Using IMS Health sales data, we described
the trajectories of sales volumes of the study medicines between January 2001 and Decem-
ber 2012. We compared estimated average numbers of patients treated before and after
the implementation of policies and programs for each product.
Results
Different stakeholders implemented multiple interventions to increase access to the study
medicines for different patient populations. During 2007–2009, the Thai Government creat-
ed a special NLEM category with different coverage requirements for payers and issued
compulsory licenses; payers negotiated prices with manufacturers and engaged in pooled
procurement; pharmaceutical companies expanded patient assistance programs and low-
ered prices in different ways. Compared to before the interventions, estimated numbers of
patients treated with each medicine increased significantly afterwards: for letrozole from
645 (95% CI 366–923) to 3683 (95% CI 2,748–4,618); for imatinib from 103 (95% CI 72–
174) to 350 (95% CI 307–398); and for trastuzumab from 68 (95% CI 45–118) to 412 (95%
CI 344–563).
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Conclusions
Government, payers, and manufacturers implemented multi-pronged approaches to facili-
tate access to targeted cancer therapies for the Thai population, which differed by medicine.
Routine monitoring is needed to assess clinical and economic impacts of these strategies in
the health system.
Introduction
Cancer constitutes a major disease burden especially in low- and middle-income countries
(LMICs), where most health systems are ill-prepared to meet the challenges of providing and
financing cancer care.[1,2,3] More than half of the 12.4 million new cases of cancer in 2008
and almost two-thirds of the annual 7.6 million deaths from cancer occurred in LMICs.[4,5]
By 2030, an estimated 27 million new cancer cases and 17 million cancer deaths will occur in
LMICs.[2] Cancer impacts the health and emotions of patients and families, and the costs of
cancer care can impoverish both families and health systems.
Cancer survival tends to be poorer in developing countries than developed ones. In devel-
oped countries, cancer treatment is a priority and well-functioning health care infrastructures
often facilitate earlier cancer detection, better access to treatment, and reduction of mortality.
[6] With limited resources for health, LMICs struggle to guarantee access for all members of
society to needed cancer treatments, especially innovative but expensive cancer medicines.[7,8]
Targeted cancer therapies which act on specific molecules involved in tumor growth and pro-
gression play a significant role in modern cancer care; new medicines are estimated to account
for 50–60 percent of the increase in cancer survival rates in high-income countries since 1975.
[9] Due to the high costs of these innovative medicines, many cancer patients, particularly in
LMICs, face substantial financial barriers to accessing promising treatments.
Many countries are striving toward universal health coverage (UHC), intending to ensure
that everyone has access to needed health services without incurring financial hardship.[10,11]
UHC proponents aim to overcome major inequalities in access to care, inadequate risk protec-
tion, poor affordability of health services, and high household out-of-pocket health expendi-
tures.[7] While countries may embark on different paths toward UHC,[12] all policy makers
face resource constraints and competing health priorities when making difficult decisions
about providing access to innovative cancer medicines for their populations. Governments fre-
quently use health technology assessment (HTA) to decide which cancer medicines to list as es-
sential medicines and to cover through insurance or by public subsidy systems. Pharmaceutical
companies may also facilitate access by lowering prices and providing free medicines to specific
patients. Evidence is needed on the effects of different strategies that facilitate access to innova-
tive cancer medicines in systems working toward UHC.
In Thailand, an upper-middle income country in South-East Asia, cancer is a leading cause
of death.[13,14] From 2003 to 2011, the mortality rate from cancer rose from 79 to 95 per
100,000 population.[13] Thailand implemented a comprehensive strategy toward universal
health coverage in 2002, after which all Thais were covered by health insurance guaranteeing
access to a comprehensive package of health services.[15] In 2013, the Civil Servant Medical
Benefit Scheme (CSMBS) for government employees covered 7.6 percent of the population,
[16] the Social Security Scheme (SSS) for private sector employees another 16.1 percent, and
the rest of the population (76.3 percent) was enrolled in the Universal Coverage (UC) Scheme,
[16] which covers everyone regardless of socioeconomic status. Member contributions, medical
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and pharmacy benefits, and reimbursement procedures differ between the three schemes.[17]
For members of the UC and SSS schemes, medicines listed on the National List of Essential
Medicines (NLEM) are covered under a capitated benefit when prescribed during ambulatory
care, or under case-based reimbursement when prescribed for and administered to inpatients.
UC and SSS members need to pay out of pocket for medicines not listed on the NLEM. For
CSMBS patients, providers receive fee-for-service payments; most NLEM and non-NLEM
medicines are free of charge for CSMBS members.
Since the health care reform in 2001,[18,19] several stakeholders have initiated policies and
programs to facilitate access to medicines. The Thai government implemented an evidence-
based process for selecting medicines for the NLEM, established a minimummedicines reim-
bursement list, exercised the World Trade Organization (WTO) Trade-Related Aspects of In-
tellectual Property Rights (TRIPs) provisions for several medicines,[20,21] and adopted HTA
for making decisions about whether new technologies should be added to the NLEM.[13]
In 1981, the Thai government issued its first NLEM.[22] The tenth version of the NLEM,
published in September, 2013,[23] lists 832 medicines considered essential for treating the
health problems of Thai people.[2] The list is the basis for medicines procurement by public
hospitals and constitutes the minimum reimbursement list for all major health insurance
schemes. Medicines are selected based on whether they meet health needs, as well as safety, effi-
cacy, quality, cost-effectiveness and national affordability criteria.[20] For innovative and high
cost medicines deemed important, the NLEM Committee also conducts HTAs to determine
their cost-effectiveness and budget impact to support NLEM decision making.[20,24] Current-
ly, the NLEM comprises five major categories of medicines based on indications, appropriate-
ness, and prescribing requirements: categories A-C comprise the medicines necessary to treat
common diseases at every level of hospital; category D contains medicines that may be life-sav-
ing for some patients[2] but require expert diagnosis before prescribing; and category E con-
tains specialized medicines that require pre-approval and patient laboratory monitoring. A
limited number of innovative cancer medicines have been included in the NLEM since 1981: of
26 targeted cancer therapies approved in Thailand, four are listed in the 2013 NLEM.[2,25] In
addition, the Thai government has also implemented compulsory licensing (CL) under TRIPs;
the Thai Ministry of Public Health granted CLs for four patented cancer drugs in January,
2008: letrozole for breast cancer, docetaxel for breast and lung cancers, erlotinib for lung can-
cer, and imatinib for chronic myelocytic leukemia (CML) and gastrointestinal stromal tumour
(GIST).[26,27] Compulsory licenses, when implemented, allow the government to produce or
import less expensive generic versions of the respective drugs without agreement of the patent
holder, However, before the implementation of CL for cancer drugs products, the government
allowed patent-owners to lower prices of the respective branded products, in lieu of issuing a
CL.
Other stakeholders have also implemented programs to increase access to innovative cancer
medicines. Through patient assistance programs, companies collaborate with non-government
organisations (NGOs) to provide free medicines to selected individual patients.[28] Govern-
ment suppliers pool purchasing of bulk volumes and negotiate special purchasing arrange-
ments with companies resulting in lower prices.
Thailand’s experiences may inform other countries on the path to UHC. However, no sys-
tematic assessment exists of the impacts of strategies implemented by different stakeholders in
Thailand to increase access to innovative cancer therapies. Thus, the objectives of the present
study were to: a) describe the policy and program approaches by different health system stake-
holders in Thailand to facilitate access to targeted cancer therapies; and b) analyze utilization
of selected targeted cancer treatments over time.
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Methods
Selection of targeted therapies
Ethical approval was granted by the IRB of Harvard Pilgrim Health Care Institute. Using IMS
Health data (described below) [9, 10], we identified all cancer treatments from three therapeu-
tic classes [antineoplastics, immunostimulating agents, and cytostatic hormones, as classified
by the European Pharmaceutical Research Association Anatomical Therapeutic Chemical
(ATC) system] on the market in Thailand in 2012 (n = 107 different molecules). Of 76 cancer
medicines launched before 2001, seven (9%) were targeted therapies, versus 19 (60%) of 31
launched during 2001–2012.
Four targeted therapies [two launched before 2001 (basiliximab and letrozole) and two
launched during 2001–2012 (imatinib and bevacizumab)] were listed in the 2013 NLEM.[2]
We selected two listed products: letrozole, which is indicated for breast cancer, the most com-
mon cancer in Thailand;[29] and imatinib, which is indicated for the treatment of Philadelphia
chromosome positive (CML-Ph+) chronic myelogenous leukemia and gastrointestinal stromal
tumors (GISTs). To illustrate policy differences, we also selected three targeted cancer therapies
used for the same indications but not listed in the NLEM: trastuzumab for breast cancer with
positive human epidermal growth factor receptor 2 (HER2+), and nilotinib and dasatinib for
treatment of CML and GISTs. [40–42]
Policy and program identification and analysis
We identified policies and programs intended to increase access to the study medicines in
Thailand in multiple ways. We searched electronic databases including PubMed[30] through
December 2013 for published articles on Thai policy changes related to cancer medicines. We
also searched for published policy documents on the websites of the Ministry of Public Health
and the three health insurance schemes (the National Health Security Office (NHSO) in charge
of the UC scheme,[31] the Social Welfare Office (SWO) in charge of the SSS,[32] and the
Comptroller General’s Department, Ministry of Finance (CGD) in charge of the CSMBS[33]).
In addition, we searched for relevant information on research institute websites, the Open Uni-
versity website, and the websites of the pharmaceutical companies. Search terms included:
(“policy” OR “intervention” OR “program” OR “patient access program” OR “patient assis-
tance program”) AND “access to medicines” AND (“targeted cancer therapies” OR “letrozole”
OR “trastuzumab”OR “imatinib” OR “nilotinib”OR “dasatinib”) AND “Thailand”. Relevant
policies and programs implemented during 2001–2012 were included.
We categorized policies and programs into three groups, according to the stakeholders who
initiated them: the central government, payers, and pharmaceutical companies. We verified
policy details in personal communications with selected stakeholders.
Analysis of medication use
We assessed the utilization of targeted cancer therapies using quarterly IMS Health sales data
from 2001 to 2012.[34] IMS Health data originate from pharmaceutical companies’ sales re-
ports and surveys of purchases by 200 of the 1100 public and private hospitals in Thailand; the
data are projected to represent total national sales. More than 85% of cancer drugs’ sales occur
in the public sector. [35] Information on medicines dispensed in public and private hospitals
under special programs initiated by pharmaceutical companies or non-governmental organiza-
tions is included in the estimates. The database contains generic drug names, product names,
pack sizes, and volumes sold in standard units. A standard unit is defined by IMS Health as the
smallest unit of a dosage form, that is, one tablet or capsule for oral products and one vial for
Policies to Facilitate Access to Cancer Therapies in Thailand
PLOS ONE | DOI:10.1371/journal.pone.0119945 March 23, 2015 4 / 17
injections. To account for population changes, we used semi-annual population estimates from
the National Statistical Office as the denominator in our analyses.[36] We depict semiannual
time series of the number of standard units sold per 100,000 people, assuming that increasing
sales volumes represent increasing access to the medicines.
We estimated the number of patients treated in a given half-year period as the total number
of courses of each targeted therapy sold divided by standard adult dose for a specific indication.
To do so, we transformed standard units into total amount of drug (in milligrams) sold and di-
vided drug amount by recommended standard doses for each indication. We used recom-
mended doses based on local clinical practice guidelines. For letrozole and imatinib, we applied
recommended doses from the 2013 NLEM [23] and obtained recommended doses for non-
NLEMmedicines (dasatinib nilotinib and trastuzumab) from local clinical practice guidelines.
[37,38,39] Dosage assumptions are listed in Table 1: letrozole 2.5 mg per day for metastatic
breast cancer in postmenopausal patients with positive hormone receptor; trastuzumab loading
dose 4 mg/kg and maintenance dose 2 mg/kg every week, assuming a standard adult women
body weight of 57 kilogram,[40] for treatment of HER2+ metastatic breast cancer patients;
imatinib 400 mg, dasatinib 100 mg and nilotinib 800 mg per day for CML-Ph+ and GISTs.
[41,42] We also assumed that patients received all treatments as detailed in the guidelines and
that all medicines were used as indicated. Using a paired Mann-Whitney U Test, we compared
median estimated numbers of patients treated across the half-year periods before to those after
the sets of policies were implemented for each targeted therapy. We calculated confidence in-
tervals around estimated median numbers of patients treated.
Results
Published literature [20,26,28,43] documented four policies intended to improve access to the
study medicines; threes additional policies were described in local documents. Policies are sum-
marized in Table 2. The government, insurance payers and pharmaceutical companies had
each initiated several policies and programs, creating a complex and changing policy environ-
ment around targeted cancer therapies. Fig. 1 presents chronological timelines of the sequence
of policy approaches over time for each medicine. Below we describe the policy and utilization
changes for each selected medicine.
Letrozole (NLEM listed)
Policy and program approaches. Government-initiated access policies: To facilitate ac-
cess to letrozole, in 2004 the government included letrozole in NLEM category D (“medicines
that are used for specific indications[2] and require specialist physician diagnosis and monitor-
ing”) for postmenopausal women with hormone-receptor-positive breast cancer.[44] Due to its
Table 1. Standard treatment of targeted cancer therapy.
Targeted cancer therapy Daily dose (mg) Treatment duration Total amount per case per quarter (mg)
Letrozole 2.5 Once daily 227.5
Trastuzumab Loading dose: 8 mg/kg Once 2,964*
Maintainance dose: 4 mg/kg Every week
Imatinib 400 Once daily 36,400
Nilotinib 800 Once daily 72,800
Dasatinib 100 Once daily 9,100
* Calculation based on a standard adult women body weight of 57 kilogram
doi:10.1371/journal.pone.0119945.t001
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high cost (approximately US$2555 per year in 2012, about 25 times the fixed capitation rate of
hospitals for SSS and UC patients[45]), letrozole was moved from NLEM category D to sub-
category E2 (“High-cost medicines: E2 access program”) that was first created in the 2008
NLEM.[46,47] The E2 access program was established for very high cost medicines considered
to be an economic burden to both society and patients[33] and for which appropriate prescrib-
ing is limited to strictly defined clinical situations. To ensure access and appropriate use, the E2
access program requires that insurers provide medicines in the NLEM E2 category free of
charge to patients who meet prior authorization requirements and for whom the products are
prescribed by qualified physicians. Different from other NLEM category drugs, insurance
schemes were given time to implement the E2 access program so that they could allocate re-
sources to cover the medicines. NHSO implemented the E2 policy for letrozole in January
2009; the SWO implemented it in June 2012.
Because of ongoing concerns about the cost of letrozole, which limited patients’ access to
the medicine, the Thai government considered exercising its WTO TRIPs flexibilities to issue a
CL for letrozole.[25,48,49,50] In September 2007, the Government granted a series of CLs to
allow the import of generic equivalents of four patented cancer medicines (i.e., imatinib, letro-
zole, docetaxel and erlotinib) into Thailand. However, beginning mid-October, 2007, the Pub-
lic Health Minister decided to negotiate prices with patent-holding pharmaceutical companies
to encourage them to expand access to their cancer drugs, possibly in lieu of a CL.[25,32] After
several rounds of negotiations, the Thai government finally implemented a CL for letrozole in
January 2008. Since no generic letrozole was available in the Thai market at the time, the gov-
ernment imported generic letrozole from India in July 2008.[25]
Payer-initiated access policies: 1) The National Health Security Office: Although letrozole
had been listed on NLEM since 2004, due to its high cost, limited numbers of UC patients re-
ceived the drug. Both NHSO and hospitals could not afford the expenditures. The implementa-
tion of a CL in September 2007 and the E2 access program in March 2008 were intended to
facilitate access. NHSO took nine months to prepare their system and became the first payer to
implement the E2 access program in January 2009.[46] All postmenopausal women with hor-
mone-receptor-positive metastatic breast cancer enrolled in UC began to receive letrozole free
of charge. For stock management and to ensure continuous supply to hospitals, NHSO worked
with the Government Pharmaceutical Organization (GPO)[51] to procure generic letrozole for
use by UC patients. GPO procures generic products from India under its aggregate medicines
procurement plan and supplies each hospital according to demand under its Vendor Managed
Table 2. Summary of policies.
Initiators Policies
Government
 National List of Essential Medicines (NLEM)
 E2 access program implementation
 Compulsory licenses (CL)
Payers
National Health Security Ofﬁce (NHSO)
 E2 access program implementation
 Pooled purchasing (price negotiation)
 Medicine reimbursement policies
Social Welfare Ofﬁce (SWO)
 E2 access program implementation
 Special marketing arrangements (price negotiation)
Comptroller General’s Department (CGD)  E2 access program implementation
Pharmaceutical companies
 Patient assistance programs
 Special marketing arrangements (price negotiation)
doi:10.1371/journal.pone.0119945.t002
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Fig 1. Chronology of government, payer, andmanufacturer policies facilitating patient access to five targeted cancer therapies.
doi:10.1371/journal.pone.0119945.g001
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Inventory (VMI) system.[46,52] 2) Social Welfare Office: Discrepancies in medical benefits be-
tween patients under UC and SSS were identified after the NHSO implemented the E2 access
program.[46] SWO patients needed to pay for target medicines because the SWO had not yet
implemented the program for SSS enrollees. After a long period of preparation, the SWO im-
plemented the E2 access program in June 2012.[53] 3) Comptroller General’s Department,
Ministry of Finance (CDG): No special access policy or program was initiated for CSMBS en-
rollees because letrozole was already covered under their fee-for-service health and
pharmacy benefits.
Utilization over time. Fig. 2(A) shows the utilization of branded and generic letrozole
over time. Based on the standard dosage of letrozole (Table 1), during the observation period,
the median estimated number of patients treated with either branded or generic letrozole in-
creased from 645 (95% CI 366–923) in the half-year periods before to 3683 (95% CI 2748–
4618) in those after the 2009 implementation of the access policies.
Between 2001 and 2008, only branded letrozole existed in the market and its use increased
steadily and substantially, from 160 to 2232 patients treated. After implementation of CL and
the E2 access program, sales per half-year per 100,000 persons of originator-brand letrozole re-
mained initially stable. Sales of two generic letrozole products (Letrozole and Trozet) that en-
tered the market in 2009 following implementation of CL rose quickly to about 200 and 50
standard units sold/100,000 persons, respectively. However, a shortage of generic letrozole im-
ported from India in the second half of 2010 prompted the NHSO to procure letrozole from
the originator company Novartis to guarantee availability at hospitals, accounting for the sud-
den 2010 peak in originator-brand letrozole (Femara) sales of about 1500 units/
100,000 persons.
Trastuzumab (Non-NLEM)
Policy and program approaches. Trastuzumab was approved for the treatment of meta-
static HER2+ breast cancer in Thailand in September 2000.[3] However, as of May 2014, tras-
tuzumab had not been listed on the NLEM.[2,33] Only patients covered by the CSMBS had
access the medicine free of charge; SSS and UC enrollees needed to pay out of pocket for trastu-
zumab treatment. The manufacturer submitted an application for NLEM listing in 2010 and
the NLEM committee is waiting for HTA results from the Health Economics Working Group
and a price proposed by the Price Negotiation for NLEM Selection Working Group.[20]
Pharmaceutical company initiated special marketing arrangements: To facilitate access to
trastuzumab, Roche Co. Ltd began to offer in January 2010 a program (“Buy 3 and get 1 free”)
that decreased treatment costs for self-paying patients while waiting for NLEM committee de-
cisions.[54]
Utilization over time. Fig. 2(B) shows the growth in sales of trastuzumab over time. The
sales of trastuzumab increased slightly between 2001 and 2007, and started to steeply increase
in 2006. After implementation of the company-initiated patient assistance program in 2010,
trastuzumab sales may have increased somewhat more steeply starting in 2011. Assuming that
trastuzumab was used only for metastatic breast cancer (the only CSMBS-reimbursed indica-
tion for this drug) and using standard doses for this indication (Table 1), the median estimated
number of patients treated per half year during 2001–2009 was 136 (95% CI 90–238); and 824
(95% CI 688–1,126) between 2010 and 2013.
Policies to Facilitate Access to Cancer Therapies in Thailand
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Imatinib (NLEM listed)
Policy and program approaches. Imatinib was the first tyrosine kinase inhibitor approved
for the treatment of CML in 2002 and for GISTs in 2003. Government authorities, payers and
the manufacturer have introduced policies and programs to facilitate access to imatinib.
Fig 2. Sales of selected targeted cancer therapies over time.
doi:10.1371/journal.pone.0119945.g002
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Government initiated access policies: The Thai government-issued CLs in September 2007
for four cancer drugs included imatinib. However, Novartis, the manufacturer of imatinib,
made a last minute offer to the Thai government to provide the medicine free to all patients
under the UC scheme in January 2008, provided that no CL would be issued.[50]
Similar to letrozole, imatinib was listed in March 2008 in the E2 program under the NLEM
for patients with CML-Ph+ and GISTs.[46] However, payment and distribution of imatinib for
UC-covered patients remained under GIPAP (described below).
Payer initiated access policies: Since February 2008, selected CML patients covered by the
UC scheme received imatinib free of charge under the Glivec International Patient Assistance
Program (GIPAP). Some patients covered under the SSS received imatinib for half the original
price, following price negotiations between the company and selected hospitals that engaged in
negotiations. The different payers then implemented the imatinib E2 access program at differ-
ent times, the NHSO in January 2009 and the SWO in June 2012. While approaches differed by
scheme, they involved agreements with the manufacturer Novartis described below.
Pharmaceutical company initiated access programs: GIPAP had been set up in Thailand
since January 2003 by Novartis Co Ltd. to facilitate access to and distribution of imatinib di-
rectly to CML patients though registered hospitals. The program aimed to fill the gaps in access
for eligible patients who could not afford the costly treatment.[55] Under the program, patients
must be diagnosed by a GIPAP-qualified physician. Physicians submit an application on behalf
of each patient. The physician is required to be involved in all stages of treatment, including di-
agnosis, prescription, and follow-up. Patient applications are assessed by the Max Foundation,
a US-based non-profit patient organization specialized in CML, based on specific medical and
socio-economic criteria [51, 52]. Eligible patients are UC patients diagnosed with CML-Ph+ or
CD117 positive GIST whose household incomes are less than 100,000 baht (US$3,225) per
year. The administration of the program by independent third parties is intended to ensure in-
dependence in the evaluation and approval of patients. If approved, Novartis supplied imatinib
though hospitals every three months based on requests from the treating physicians.
After negotiations with the Thai government to avert CL in January 2008, the company
agreed to expand the GIPAP program and provided imatinib free of charge to all UC patients
for the treatment of CML and GISTs. All patient applications are assessed by the Max Founda-
tion and Novartis is responsible for drug distribution; in addition, Novartis also needs to share
information about eligible patients with the NHSO for their records.
For SSS patients with CML-Ph+ who needed to pay out-of-pocket for imatinib at the time,
the company had proposed in June 2003 a 50% price reduction to interested hospitals. It was
unclear from public documents how many hospitals participated in the price negotiation. In
July 2012, following negotiations between the company and the SWO, the 50% price reduction
was extended to all SSS-contracted hospitals.
Utilization over time. Fig. 2(C) shows the utilization of imatinib over time. Since GIPAP
implementation in 2003, imatinib use rose continually. Following expansion of the GIPAP pro-
gram to all UC patients and licensing of alternative tyrosine kinase inhibitors, utilization of
imatinib dropped briefly in the first half of 2009 but continued to increase and possibly more
steeply following the 2012 price reduction for SSS patients.
Based on standard dosages of imatinib (Table 1), the median estimated number of patients
treated increased significantly from 103 (95% CI 72–174) before to 350 (95% CI 307–398) after
the 2009 implementation of the policies and programs.
Policies to Facilitate Access to Cancer Therapies in Thailand
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Nilotinib and Dasatinib (Non-NLEM)
Policy and program approaches. Nilotinib and dasatinib are second-generation tyrosine-
kinase inhibitors for the treatment of CML-Ph+ and GISTs, similar to imatinib. They were ap-
proved for sale in Thailand in September and October 2008, respectively.
Pharmaceutical company initiated access program: The Tasigna International Patient Assis-
tance Program (TIPAP) is a patient assistance program initiated in January 2009 by the manu-
facturer Novartis Co. Ltd. to facilitate access to nilotinib for CML-Ph+ and GIST patients who
did not respond to or unable to tolerate imatinib and cannot afford the treatment.[18] Like
GIPAP, the Max Foundation operates the TIPAP program for selected patients with financial
problems defined as those with household incomes less than 100,000 baht (US$3,225 in May
2014) per year and covered by the UC scheme.
Utilization over time. Fig. 2(C) shows the utilization of nilotinib and dasatinib. After nilo-
tinib and dasatinib were launched, sales increased over time, with volume of use per half-year
per 100,000 persons of nilotinib higher than that of dasatinib during the study period. Since
the products were launched, the estimated numbers of patients treated (based on standard
daily doses in Table 1) were 39 (95% CI 24–60) and 20 (95% CI 10–25) for nilotinib and
dasatinib, respectively.
Discussion
In pluralistic health care financing systems, no single policy strategy can provide access to
high-cost medicines for all who need them. Multi-pronged approaches are needed, imple-
mented by multiple stakeholders who cooperate and negotiate within their realms of responsi-
bilities and constraints. Our study described how government, payers, and pharmaceutical
companies used various tools to increase access to targeted cancer medicines for different pa-
tient populations in Thailand. Not surprisingly, use of NLEM listed agents (letrozole and imati-
nib) was substantially higher than that of the unlisted drugs (trastuzumab, nilotinib, and
dasatinib) for the same indications. However, stakeholders also implemented programs that
made access possible for unlisted drugs in Thailand. Overall, various programs seem to have
complemented each other in increasing use of the cancer medicines studied.
The goal of universal health coverage (UHC) is to ensure that all people can obtain the
health services they need while protecting households from impoverishing out-of-pocket
health spending.[56] One of the key factors that must be considered when implementing UHC
is access to needed medicines.[56] Without access to medicines, countries cannot progress to-
ward goals to reduce the number of avoidable deaths due to common conditions and increase
survival of patients with severe diseases such as cancer. Along with preventing illness, ensuring
equitable access to appropriate and affordable pharmacological treatment is crucial to achiev-
ing UHC and financial protection goals.
Thailand introduced UHC in 2002 and initiated a number of policies to achieve and sustain
universal coverage implementation. To facilitate access to targeted cancer medicines, several
stakeholders initiated different policies based on their authorities in the Thai health system.
The Thai government ensured the availability of medicines by implementing the NLEM for all
Thai people and payers applied the NLEM as the minimum reimbursement list for their enroll-
ees. The Thai government then listed selected high-cost medicines in a new E2 subcategory of
the NLEM, with a requirement of coverage over time, once financing for E2 category drugs was
feasible. To make financing more feasible, the government and payers negotiated with compa-
nies to decrease prices.
To make medicines more affordable, payers pooled procurement and negotiated lower
prices, saving hundreds of million baht annually.[57] Since January 2013, the SWO transferred
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its budget to NHSO to participate in pooled procurement and delivery of E2 medicines for SSS
patients. Larger volumes, for more than 90% of total Thai population, are expected to increase
negotiation power and to decrease purchasing prices further.
To make medicines more affordable, the Thai government also implemented highly contro-
versial CL. To ensure the quality of generic medicines imported after the implementation of
CL, the Thai Food Drug and Administrative (FDA) addressed Thailand’s drug qualification
standards in the drug registration system, and implemented a post-import surveillance system
and a drug quality reporting system.[50,58] An assessment of the impacts of CL suggested that
importing less expensive generic medicines following CL resulted in savings in excess of US
140 million for the use of three cancer medicines over 5 years.[27] Although some had raised
concerns about the negative effects of CL on trade, the study found no negative impacts on
Thailand’s exports. Although CL constituted a legitimate strategy and seems to have benefitted
the Thai health system, CL may not be a desirable policy strategy to improve access to medi-
cines in every system: CL depends on national and international political circumstances, re-
quires potentially confrontational actions, and is administratively cumbersome as it usually
applies to one drug and one company at a time.
For non-listed NLEMmedicines, pharmaceutical companies made medicines accessible to
selected patients by introducing patient assistance programs and special marketing arrange-
ments. An exemplary patient assistance program, GIPAP, was offered by Novartis in Thailand
since 2003. Initially, this program was set up and managed by the company because imatinib
was not listed on the Thai NLEM at that time. The program provided access to the drug for
1380 poor patients during the first five years of its implementation.[59] After the negotiations
between the government and the pharmaceutical company, and to avoid CL, Novartis expand-
ed the GIPAP program to cover all eligible UC patients since 2008. Following the successful ne-
gotiation and coverage expansion, the NLEM subcommittee listed imatinib on the 2008
NLEM. Although there is a trend in increased use of patient assistance programs, these pro-
grams tend to be heterogeneous, varying across hospitals, highly dependent on the continued
support of manufacturers and visionary policy makers, and subject to the readiness of the de-
livery system to support provision of comprehensive care.[60] Implementing such programs
efficiently on a large scale requires agreements among stakeholders, investments in health sys-
tem infrastructure, and close monitoring so that eligible patients in need receive continued ac-
cess to medicines.[61]
Under UHC expansion, expenditures are intended to shift from out-of-pocket (OOP)
spending to public health expenditures.[62] Between 1995 and 2009, Thailand increased public
health spending by 6.2 percent annually while out-of-pocket spending on health fell by 3.4 per-
cent annually,[63] a development often cited as testimony to the successful achievement of
UHC in Thailand.[64,65] Recently, the list of E2 medicines has been expanded and now in-
cludes 16 products (4 oncology medicines and 12 other essential medicines) indicated for 27
conditions.[2] Given the increasing needs for and availability of novel, usually very expensive
treatments for cancer and other conditions, an important question concerns the financial sus-
tainability of the health system. At a minimum, routine and careful monitoring of expenditures
is needed to intervene as needed to ensure sustainability. In addition, other tools to increase ac-
cess to novel medicines will likely be required in the context of limited financial resources, in-
cluding risk-sharing schemes[66] and other public-private collaborations. Risk-sharing
schemes are agreements between a payer and a pharmaceutical company in which the partners
negotiate the price of a product and/or the overall spending depending on volumes sold, clini-
cal outcomes achieved or patient populations who receive the drug.[67,68] The intent is that
companies share the financial risk of payers to cover the drug, and pay for the drug when an
agreed volume or budget is exceeded, or intended clinical outcomes are not achieved. Even
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broader public-private partnerships engage multiple actors to pursue long-term goals such as
cancer control and health system strengthening.[69] Importantly, studies are needed to evalu-
ate the impacts of expanding access to novel medicines on health outcomes for specific patient
populations and the opportunity costs and health benefits achieved in the system as a whole.
Our study has a number of limitations. First, because interventions were multiple and in
close proximity, we were unable to test whether discontinuities in market growth were due to
specific policy changes using formal statistical methods such as interrupted time-series analy-
sis. Instead, we estimated numbers of patients treated based on several conservative assump-
tions about use of the products in question for specific indications and at fixed recommended
doses. To compare estimates, we applied the same assumptions in both pre- and post-policy
implementation periods. Differences in estimated numbers of patients treated based on differ-
ences in product volumes sold could have occurred because of changes in therapeutic regimens
over time, general market growth, or the complexities of supply systems and stock manage-
ment. Nevertheless, visual inspection of market trajectories is a useful analytic tool. For exam-
ple, we identified fluctuations of letrozole sales that were explained by pooled purchasing from
GPO during 2010–2011. Second, we did not explore policies initiated by non-profit interna-
tional organizations (i.e. donation programs). Such programs may provide targeted cancer
therapies for specific patients. Nevertheless, our study captured policies that were initiated by
key stakeholders at national and hospital levels. Third, given the lack of reliable epidemiologic
and clinical data (including incidence of specific cancers, percentage of patients in each stage,
percentage of patients receiving chemotherapy), we could not estimate the percentages of can-
cer patients in Thailand who would be eligible for the specific cancer therapies or the changes
in patients receiving medicines among eligible patients. Fourth, because IMS Health sales data
are estimates of national sales based on sampled hospital data, changes over time in relevant
characteristics of hospitals—such as registration status with GPAP or whether a hospital nego-
tiates prices with manufacturers—, compared to changes in composition of sample hospitals,
may have biased our estimates of changes in imatinib sales. Lastly, given our use of IMS sales
data, we were unable to assess whether access to the targeted therapies was equitable or whether
the medicines were used appropriately. Individual-level data including patient demographic
and clinical characteristics are needed to study equity in access and appropriateness of medica-
tion use. To do so, routine data should be collected to monitor and evaluate policies and pro-
grams for access to targeted cancer therapies, both from the perspectives of cancer care and
overall health care in the system.
Conclusions
Our findings highlight the interplay of policies initiated by different stakeholders to increase
access to high-cost medicines. Although policy processes are likely to be highly context-specif-
ic, other countries may learn from the Thai experience. Key lessons include the importance of
consistent political support and cooperation among health system stakeholders. No single ap-
proach is likely to facilitate access to targeted cancer therapies for all who need them; multiple
approaches are needed that differ by stakeholder, by the nature of the target population, and by
the regulatory status of each medicine. Continued research is needed to assess whether the uti-
lization of expensive medicines is equitable, clinically appropriate and effective, and affordable
at household and system levels.
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